Duloxetine Capsule, Delayed Release
Product Images NDC 70518-2630

17 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-2630). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Duloxetine Structure)

Structure (Duloxetine Structure)
Chemical structure of duloxetine hydrochloride showing its molecular composition and arrangement in a two-dimensional diagram.*
FDA Label Image

Figure1 (Duloxetine Fig1)

Figure1 (Duloxetine Fig1)
A Kaplan-Meier curve chart comparing the proportion of patients experiencing relapse over time (in days) between Duloxetine and placebo treatments. The x-axis represents time from randomization to relapse, and the y-axis shows the proportion of patients with relapse. Duloxetine shows a lower relapse proportion over time compared to placebo.*
FDA Label Image

Figure2 (Duloxetine Fig2)

Figure2 (Duloxetine Fig2)
A line graph comparing the proportion of patients with relapse over time from randomization (in days) between Duloxetine and placebo treatments. The x-axis shows time in days up to 300, and the y-axis shows the proportion of patients with relapse ranging from 0.0 to 1.0. The graph includes a legend identifying Duloxetine with a solid line and placebo with a dashed line.*
FDA Label Image

Figure3 (Duloxetine Fig3)

Figure3 (Duloxetine Fig3)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Four groups are compared: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, each represented by different markers. The graph shows higher percentages of patients improved with Duloxetine doses compared to placebo across increasing pain improvement percentages.*
FDA Label Image

Figure4 (Duloxetine Fig4)

Figure4 (Duloxetine Fig4)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The y-axis represents the percentage of patients improved, and the x-axis represents the percent improvement in pain from baseline.*
FDA Label Image

Figure5 (Duloxetine Fig5)

Figure5 (Duloxetine Fig5)
A line graph showing the percentage of patients improved against percent improvement in pain from baseline. Three data series are plotted: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo, illustrating their comparative effectiveness in pain improvement over a range of percent improvement values.*
FDA Label Image

Figure6 (Duloxetine Fig6)

Figure6 (Duloxetine Fig6)
A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, 20 mg once daily, and a placebo. The graph shows data trends for these four groups, illustrating their relative effectiveness in pain improvement.*
FDA Label Image

Figure7 (Duloxetine Fig7)

Figure7 (Duloxetine Fig7)
A line graph comparing percentage of patients improved versus percent improvement in pain from baseline. Two lines represent Duloxetine 60 mg once daily and placebo, showing higher improvement rates with Duloxetine across increasing pain improvement intervals.*
FDA Label Image

Figure8 (Duloxetine Fig8)

Figure8 (Duloxetine Fig8)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis indicates percent improvement in pain from 0% to 100%, and the y-axis shows the percentage of patients improved from 0% to 100%. Duloxetine consistently shows higher patient improvement percentages across most pain improvement intervals compared to placebo.*
FDA Label Image

Figure9 (Duloxetine Fig9)

Figure9 (Duloxetine Fig9)
A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The x-axis shows increasing percent improvement in pain, while the y-axis shows the percentage of patients improved. Two lines represent Duloxetine and placebo, with Duloxetine consistently showing higher percentages across increasing pain improvement thresholds.*
FDA Label Image

Figure10 (Duloxetine Fig10)

Figure10 (Duloxetine Fig10)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo and Duloxetine 60/120 mg once daily, showing higher patient improvement percentages with Duloxetine across increasing pain improvement thresholds.*
FDA Label Image

Mm1 (Duloxetine 60mg 70518 2630 00)

Mm1 (Duloxetine 60mg 70518 2630 00)
Duloxetine Capsule delayed-release 60 mg label for a bottle containing 60 capsules. The label shows the product NDC 70518-2630-00 and indicates the capsules are white/blue. Manufactured by Ajanta Pharma Ltd., India, and repackaged by RemedyRepack Inc., Indiana, PA. Storage and dosage instructions are included.*
FDA Label Image

Mm2 (Duloxetine 60mg 70518 2630 01)

Mm2 (Duloxetine 60mg 70518 2630 01)
Duloxetine 60 mg delayed-release capsule label showing quantity of 30 capsules. The label includes the NDC number 70518-2630-01, manufacturing information from Ajanta Pharma Ltd. in India, and repackaging details by RemedyRepack Inc. Dosage instructions refer to the package insert, and storage temperature guidelines are provided.*
FDA Label Image

Mm3 (Duloxetine 60mg 70518 2630 02)

Mm3 (Duloxetine 60mg 70518 2630 02)
Duloxetine 60 mg delayed-release capsule label showing a quantity of 90 capsules. The label includes directions to see the package insert, storage temperature instructions, and indicates repackaging by RemedyRepack Inc. Manufacturing is noted from Ajanta Pharma Ltd., Paithan, India. The label shows the NDC 70518-2630-02 with placeholders for expiration and lot number.*
FDA Label Image

Mm4 (Duloxetine 60mg 70518 2630 03)

Mm4 (Duloxetine 60mg 70518 2630 03)
Label for Duloxetine delayed-release capsules, 60 mg strength, containing 180 capsules per package. The capsule color is white and blue. The label indicates the product is repackaged by RemedyRepack Inc., based in Indiana, PA. Manufacturer is Ajanta Pharma Ltd., Paithan, India. Storage instructions and usual dosage note to see insert are also present.*
FDA Label Image

Mm5 (Duloxetine 60mg 70518 2630 04)

Mm5 (Duloxetine 60mg 70518 2630 04)
Duloxetine Capsule 60 mg delayed-release oral capsules, packaged 100 per box. The label shows the product is repackaged by RemedyRepack Inc., Indiana, PA. The original manufacturer is Ajanta Pharma Ltd., Paithan, India. The label includes storage instructions, usual dosage advisory to see insert, and a QR code.*
FDA Label Image

Mm6 (Duloxetine 60mg 70518 2630 05)

Mm6 (Duloxetine 60mg 70518 2630 05)
Label for Duloxetine Capsule delayed-release 60 mg, containing 1 capsule per package. The capsule is described as white/blue. Labeled by RemedyRepack Inc., Indiana, PA. Includes storage instructions and manufacturer information (Ajanta Pharma Ltd., India). Contains NDC 70518-2630-05.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.